View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar Bőr-, Nemikórtani és Bőronkológiai Klinika Budapest Mária u. 41. 1085
  • 2 Semmelweis Egyetem, Általános Orvostudományi Kar III. Belgyógyászati Klinika Budapest
  • 3 Semmelweis Egyetem, Általános Orvostudományi Kar I. Patológiai és Kísérleti Rákkutató Intézet Budapest
Open access

Bevezetés: A mastocytosis a hízósejtek (mastocyták) felszaporodásával járó ritka megbetegedés, amely a WHO-besorolás szerint cutan és szisztémás formákra osztható. A klinikai tünetekhez a hízósejtek szöveti infiltrációja és/vagy a mediátorfelszabadulás vezet. Célkitűzés: A szerzők a Semmelweis Egyetem Mastocytosis Hálózat részeként a jellegzetes bőrtüneteket mutató betegek kivizsgálásával szerzett tapasztalatainak összefoglalását tűzték ki célul. Módszer: Összesen 22 mastocytosisos felnőtt beteget vizsgáltak. A diagnózis felállítása bőrszövettani vizsgálat, csontvelővizsgálat, D816V szomatikus c-KIT-mutációanalízis alapján történt. Eredmények: Húsz beteg esetében urticaria pigmentosát, egy esetben teleangiectasia macularis eruptiva perstanst észleltek. A bőr szövettani vizsgálata minden esetben igazolta a klinikai diagnózist. Cristabiopsziával 9/12 esetben a csontvelői részvétel alapján indolens szisztémás mastocytosis diagnózisa volt felállítható. c-KIT-mutációt (D816V) egy betegben igazoltak mind a csontvelőben, mind a bőrben. A betegek a klinikum függvényében antihisztamin, PUVA, a c-kit-szekvenálás eredménye alapján alfa-interferon vagy tirozinkináz-gátló terápiában részesültek. Következtetések: A mastocytosis diagnózisának felállításában a bőrgyógyász szerepe kiemelten fontos, de a betegség kiterjedtségének tisztázására a csontvelő vizsgálatát minden esetben tanácsos elvégezni. Orv. Hetil., 2013, 154, 1469–1475.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Robyn, J., Metcalfe, D. D.: Systemic mastocytosis. Adv. Immunol., 2006, 89, 169–243.

    Metcalfe D. D. , 'Systemic mastocytosis ' (2006 ) 89 Adv. Immunol. : 169 -243.

  • Hartmann, K., Henz, B. M.: Cutaneous mastocytosis – clinical heterogeneity. Int. Arch. Allergy Immunol., 2002, 127, 143–146.

    Henz B. M. , 'Cutaneous mastocytosis – clinical heterogeneity ' (2002 ) 127 Int. Arch. Allergy Immunol. : 143 -146.

    • Search Google Scholar
  • Fearfield, L. A., Francis, N., Henry, K., et al.: Bone marrow involvement in cutaneous mastocytosis. Br. J. Deramatol., 2001, 144, 561–566.

    Henry K. , 'Bone marrow involvement in cutaneous mastocytosis ' (2001 ) 144 Br. J. Deramatol. : 561 -566.

    • Search Google Scholar
  • Czarnetzki, B. M., Kolde, G., Schoemann, A., et al.: Bone marrow findings in adult patients with urticaria pigmentosa. J. Am. Acad. Dermatol., 1988, 18, 45–51.

    Schoemann A. , 'Bone marrow findings in adult patients with urticaria pigmentosa ' (1988 ) 18 J. Am. Acad. Dermatol. : 45 -51.

    • Search Google Scholar
  • Lennartsson, J., Jelacic, T., Linnekin, D., et al.: Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells, 2005, 23, 16–43.

    Linnekin D. , 'Normal and oncogenic forms of the receptor tyrosine kinase kit ' (2005 ) 23 Stem Cells : 16 -43.

    • Search Google Scholar
  • Longley, B. J. Jr., Metcalfe, D. D., Tharp, M., et al.: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. USA, 1999, 96, 1609–1614.

    Tharp M. , 'Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis ' (1999 ) 96 Proc. Natl. Acad. Sci. USA : 1609 -1614.

    • Search Google Scholar
  • Longley, B. J., Reguera, M. J., Ma, Y.: Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk. Res., 2001, 25, 571–576.

    Ma Y. , 'Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy ' (2001 ) 25 Leuk. Res. : 571 -576.

    • Search Google Scholar
  • Metcalfe, D. D.: Mast cells and mastocytosis. Blood, 2008, 112, 946–956.

    Metcalfe D. D. , 'Mast cells and mastocytosis ' (2008 ) 112 Blood : 946 -956.

  • Rausz, E., Szilágyi, A., Nedoszytko, B., et al.: Comparative analysis of IL6 and IL6 receptor gene polymorphisms in mastocytosis. Br. J. Haematol., 2013, 160, 216–219.

    Nedoszytko B. , 'Comparative analysis of IL6 and IL6 receptor gene polymorphisms in mastocytosis ' (2013 ) 160 Br. J. Haematol. : 216 -219.

    • Search Google Scholar
  • Akin, C., Valent, P., Metcalfe, D. D.: Mast cell activation syndrome: Proposed diagnostic criteria. J. Allergy Clin. Immunol., 2010, 126, 1099–1104.

    Metcalfe D. D. , 'Mast cell activation syndrome: Proposed diagnostic criteria ' (2010 ) 126 J. Allergy Clin. Immunol. : 1099 -1104.

    • Search Google Scholar
  • Swerdlow, S. H., Campo, E., Harris, N. L., et al.: WHO classification of tumours of hematopoetic and lymphoid tissues. 4th edition. International Agency for Research on Cancer (IARC), Lyon (France), 2008, 54–63.

    Harris N. L. , '', in WHO classification of tumours of hematopoetic and lymphoid tissues , (2008 ) -.

    • Search Google Scholar
  • Tefferi, A., Vardiman, J. W.: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 2008, 22, 14–22.

    Vardiman J. W. , 'Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms ' (2008 ) 22 Leukemia : 14 -22.

    • Search Google Scholar
  • Várkonyi, V.: Systemic mastocytosis. [Szisztémás mastocytosis.] Magy. Belorv. Arch., 2009, 62, 179–186. [Hungarian]

    Várkonyi V. , 'Systemic mastocytosis. [Szisztémás mastocytosis.] ' (2009 ) 62 Magy. Belorv. Arch. : 179 -186.

    • Search Google Scholar
  • Jensen, R. T.: Gastrointestinal abnormalities and involvement in systemic mastocytosis. Heamatol. Oncol. Clin. North Am., 2000, 14, 579–623.

    Jensen R. T. , 'Gastrointestinal abnormalities and involvement in systemic mastocytosis ' (2000 ) 14 Heamatol. Oncol. Clin. North Am. : 579 -623.

    • Search Google Scholar
  • Mekori, Y. A.: Lymphoid tissues and the immune system in mastocytosis. Heamatol. Oncol. Clin. North Am., 2000, 14, 569–577.

    Mekori Y. A. , 'Lymphoid tissues and the immune system in mastocytosis ' (2000 ) 14 Heamatol. Oncol. Clin. North Am. : 569 -577.

    • Search Google Scholar
  • Travis, W. D., Li, C. Y., Bergstralh, E. J., et al.: Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine, 1988, 67, 345–368.

    Bergstralh E. J. , 'Systemic mast cell disease. Analysis of 58 cases and literature review ' (1988 ) 67 Medicine : 345 -368.

    • Search Google Scholar
  • Rogers, M. P., Bloomingdale, K., Murawski, B. J., et al.: Mixed organic brain syndrome as a manifestation of systemic mastocytosis. Psychosom. Med., 1986, 48, 437–447.

    Murawski B. J. , 'Mixed organic brain syndrome as a manifestation of systemic mastocytosis ' (1986 ) 48 Psychosom. Med. : 437 -447.

    • Search Google Scholar
  • Ramsay, D. B., Stephen, S., Borum, M., et al.: Mast cells in gastrointestinal disease. Gastroenterol. Hepatol. (N. Y.), 2010, 6, 772–777.

    Borum M. , 'Mast cells in gastrointestinal disease ' (2010 ) 6 Gastroenterol. Hepatol. (N. Y.) : 772 -777.

    • Search Google Scholar
  • Rama, T. A., Côrte-Real, I., Gomes, P. S., et al.: Mastocytosis: oral implications of a rare disease. J. Oral Pathol. Med., 2011, 40, 441–450.

    Gomes P. S. , 'Mastocytosis: oral implications of a rare disease ' (2011 ) 40 J. Oral Pathol. Med. : 441 -450.

    • Search Google Scholar
  • Barton, J., Lavker, R. M., Schechter, N. M., et al.: Treatment of urticaria pigmentosa with corticosteroids. Arch. Dermatol., 1985, 121, 1516–1523.

    Schechter N. M. , 'Treatment of urticaria pigmentosa with corticosteroids ' (1985 ) 121 Arch. Dermatol. : 1516 -1523.

    • Search Google Scholar
  • Lavker, R. M., Schechter, N. M., Guzzo, C., et al.: Aggressive topical corticosteroid therapy: a novel approach to mast-cell-dependent cutaneous disorders. Dermatologica, 1987, 175, 213–216.

    Guzzo C. , 'Aggressive topical corticosteroid therapy: a novel approach to mast-cell-dependent cutaneous disorders ' (1987 ) 175 Dermatologica : 213 -216.

    • Search Google Scholar
  • Godt, O., Proksch, E., Streit, V., et al.: Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology, 1997, 195, 35–39.

    Streit V. , 'Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis ' (1997 ) 195 Dermatology : 35 -39.

    • Search Google Scholar
  • Gobello, T., Mazzanti, C., Sordi, D., et al.: Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study. J. Am. Acad. Dermatol., 2003, 49, 679–684.

    Sordi D. , 'Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study ' (2003 ) 49 J. Am. Acad. Dermatol. : 679 -684.

    • Search Google Scholar
  • Prignano, F., Toriano, M., Lotti, T.: Cutaneous mastocytosis: successful treatment with narrowband ultraviolet B phototherapy. Clin. Exp. Dermatol., 2010, 35, 914–915.

    Lotti T. , 'Cutaneous mastocytosis: successful treatment with narrowband ultraviolet B phototherapy ' (2010 ) 35 Clin. Exp. Dermatol. : 914 -915.

    • Search Google Scholar
  • Sotiriou, E., Apalla, Z., Ioannides, D.: Telangiectasia macularis eruptive perstans successfully treated with PUVA therapy. Photodermatol. Photoimmunol. Photomed., 2010, 26, 46–47.

    Ioannides D. , 'Telangiectasia macularis eruptive perstans successfully treated with PUVA therapy ' (2010 ) 26 Photodermatol. Photoimmunol. Photomed. : 46 -47.

    • Search Google Scholar
  • Simon, J., Lortholary, O., Caillat-Vigneron, N., et al.: Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol. Biol. (Paris), 2004, 52, 294–299.

    Caillat-Vigneron N. , 'Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature ' (2004 ) 52 Pathol. Biol. (Paris) : 294 -299.

    • Search Google Scholar
  • Hauswirth, A. W., Simonitsch-Klupp, I., Uffmann, M., et al.: Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk. Res., 2004, 28, 249–257.

    Uffmann M. , 'Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature ' (2004 ) 28 Leuk. Res. : 249 -257.

    • Search Google Scholar
  • Paul, C., Sans, B., Suarez, F., et al.: Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am. J. Hematol., 2010, 85, 921–925.

    Suarez F. , 'Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study ' (2010 ) 85 Am. J. Hematol. : 921 -925.

    • Search Google Scholar
  • Kluin-Nelemans, H. C., Oldhoff, J. M., van Doormaal, J. J., et al.: Cladribine therapy for systemic mastocytosis. Blood, 2003, 102, 4270–4276.

    Doormaal J. J. , 'Cladribine therapy for systemic mastocytosis ' (2003 ) 102 Blood : 4270 -4276.

    • Search Google Scholar
  • Ozdemir, D., Dagdelen, S., Erbas, T., et al.: Hypotension, syncope, and fever in systemic mastocytosis without skin infiltration and rapid response to corticosteroid and cyclosporin: A case report. Case Rep. Med., 2010, 2010, 782595.

    Erbas T. , 'Hypotension, syncope, and fever in systemic mastocytosis without skin infiltration and rapid response to corticosteroid and cyclosporin: A case report ' (2010 ) 2010 Case Rep. Med. : 782595 -.

    • Search Google Scholar
  • Bjerrum, O. W.: Interferon-α treatment in systemic mastocytosis. Curr. Drug Targets, 2011, 12, 433–436.

    Bjerrum O. W. , 'Interferon-α treatment in systemic mastocytosis ' (2011 ) 12 Curr. Drug Targets : 433 -436.

    • Search Google Scholar